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ABSTRACT Accurate assessment of idiopathic pulmonary fibrosis (IPF) disease severity is integral to the
care provided to patients with IPF. However, to date, there are no generally accepted or validated staging
systems. There is an abundance of data on using information acquired from physiological, radiological and
pathological parameters, in isolation or in combination, to assess disease severity in IPF. Recently, there
has been interest in using serum biomarkers and computed tomography-derived quantitative lung fibrosis
measures to stage disease severity in IPF. This review will focus on the suggested methods for staging IPF,
at baseline and on serial assessment, their strengths and limitations, as well as future developments.
Introduction
Idiopathic pulmonary fibrosis (IPF), the most prevalent form of the idiopathic interstitial pneumonias
(IIPs), is defined in international guidelines as “a chronic, progressively fibrosing IIP, occurring primarily
in the lungs of older adults and associated with the histopathological and/or radiologic pattern of usual
interstitial pneumonia (UIP)” [1]. Being behaviourally heterogeneous, it advances rapidly in some
individuals to produce a stepwise loss of lung function culminating in early death, while progressing more
insidiously with periods of apparent symptomatic and physiological stability in others (fig. 1). Overall, IPF
is associated with poor prognosis and a median survival time of approximately 2–3 years, as reported by
retrospective longitudinal studies dating from the late 1990s [2–6].
It is acknowledged that accurate assessment of IPF disease severity is central to the care that physicians
provide to patients with IPF. Its importance spans the entire breadth of healthcare planning and resource
provision, reimbursement of high-cost antifibrotic drugs and the design of clinical trials. One method to
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assess IPF disease severity is by staging its extent using information acquired from physiological,
radiological and pathological evaluation. As an example, based on the prevailing degree of pulmonary
function impairment and/or the extent of radiological abnormalities, IPF severity has traditionally been
described using imprecise terms such as “mild”, “moderate”, “severe”, “early” or “advanced” disease. Not
surprisingly, this approach has not gained widespread acceptance or been co-opted into routine clinical
practice. Its true prognostic value remains unclear [1].
Data potentially exist to permit more considered judgements to be made on the assessment of disease
severity using more precise variables. Indeed an increasing body of knowledge is emerging to shed light on
the relationship between selected clinical, physiological, imaging and pathological factors and mortality in
IPF [1]. Attempts have been made to integrate these determinants to refine the prognostication process
[7–9]. The potential utility of serum biomarkers as additional indicators of IPF disease severity is gaining
wider attention; the integration of biological mediator measurements or patterns of expression into
diagnostic and prognostic systems will undoubtedly be a prime focus of future IPF research [10–15].
The current absence of a generally adopted or validated tool for staging IPF is testament to the uncertainty
surrounding the optimal manner to approach this issue. This review will focus on the current means of
staging IPF severity at baseline and on serial assessment, their strengths and limitations, as well as future
developments.
Why stage patients with IPF?
Advocates of IPF staging cite a number of reasons in its support, among them a desire to improve the
quality of information that can be communicated to patients and their carers, as well as to help identify
clinical thresholds for initiating treatment, particularly in healthcare systems where such treatment is
tightly regulated. Additionally, accurate staging algorithms that can sensitively distinguish early progressive
from chronic stable disease may help in refining ongoing therapeutic decisions. A reliable method for
highlighting patients as they progress to more advanced stages of disease is also desirable, while enabling
the earlier identification of complications such as pulmonary hypertension and/or right heart failure, or
prompting a timely referral for transplant assessment or specialist end-of-life care. From a research
a) b)
c) d)
FIGURE 1 Axial computed tomography (CT) images a) at baseline and b) at a 12-month follow-up scan, in a
patient with idiopathic pulmonary fibrosis (IPF). b) Note more progressive reticulation in the right lower lobe
with new areas of subpleural reticulation in the left lower lobe (red arrows). Axial CT images in another
patient with IPF c) at baseline and d) at a 12-month follow-up scan. d) Note the progressive honeycombing
(red arrows), traction dilation of the airways (yellow arrow) and reticulation in both lobes (blue arrows).
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standpoint, therapeutic trials require sensitive markers that evaluate the change in severity of disease over
time. Furthermore, cases of mild to moderate severity IPF identified by a standardised staging protocol
may be more efficiently targeted for inclusion in observational or interventional trials [16].
Clinical, physiological and functional markers of disease severity
A number of clinical, physiological and functional variables, captured at baseline and longitudinally, have
been associated with an increased risk of mortality in IPF. Nevertheless, it is still not possible to
confidently detect IPF at an early stage, evaluate its severity in a clinically consistent manner, predict the
likelihood of response to treatment, or foretell its subsequent disease behaviour sensitively using a single
marker. The heterogeneity of phase 3 IPF trial characteristics illustrates the lack of a standardised approach
to study design as well as disagreement about optimal primary and secondary end-points. A recent
consensus effort including contributions from interstitial lung disease (ILD) experts and patients proposed
the adoption of a core set of domains and outcome measures in future clinical trials of connective tissue
disease-associated ILD (CTD-ILD) and IPF, but has yet to be put to the test [17, 18].
Clinical markers of disease severity in IPF
Dyspnoea and cough are the most common symptoms of IPF and can impact significantly on the daily
activities and health-related quality of life (HRQoL) of affected individuals. However, symptom severity per
se is notoriously difficult to quantify. The assessment of dyspnoea using the University of California San
Diego Shortness of Breath Questionnaire (UCSD-SBQ) has been used as a secondary end-point in a phase
3 trial [19]. Meanwhile, the Medical Research Council (MRC) breathlessness scale has been used to aid the
stratification of IPF disease severity [20]. When assessed longitudinally, the latter has also been shown to
predict clinical progression [21]. Although inexpensive and relatively user-friendly, most dyspnoea
assessment instruments have not been developed specifically for ILD cases such as IPF [18].
Cough has also been associated with disease progression in IPF [22]. Cough scales, questionnaires,
challenge tests and monitors are among the methods used to assess cough severity in IPF and its impact
on HRQoL [23]. The Leicester Cough Questionnaire (LCQ) has been shown to be sensitive to serial
change and is therefore considered an appropriate outcome tool in IPF trials [17, 24].
Physiological markers of disease severity in IPF
Forced vital capacity (FVC) and, to a lesser extent, diffusing capacity of the lung for carbon monoxide
(DLCO) are the most commonly used lung function parameters for denoting IPF severity, progression and
response to treatment. Longitudinal decline in FVC appears to better predict disease progression and
mortality than baseline values [25, 26]. Consequently, this parameter has become the preferred clinical
end-point in treatment trials. An absolute decline in FVC of ⩾10% or in DLCO of ⩾15% over 6 months
has been regarded as clinically important and is frequently used to describe “significant” disease
progression [27]. RICHELDI et al. [28] have proposed using the relative rather than absolute decline in 10%
of the FVC to maximise the chance of detecting disease progression with similar prognostic accuracy.
Existing data also suggest that a “marginal” (5–10%) decline in percent-predicted FVC at 6 months is
associated with increased mortality in IPF and that the minimal clinically important difference (MCID)
for this parameter is estimated to be between 2% and 6% of the baseline measurement [26, 29]. The
assessment of the slope of change in FVC using serial measurements reduces the inherent variability of
FVC measurement compared with the difference in FVC measured at two time points. It has been
proposed that daily home monitoring of FVC with a portable spirometer can provide a more sensitive and
earlier predictor of disease behaviour and outcome than periodic hospital-based measurement of the same
marker [30]. In this report, the rate of decline in FVC on daily home spirometry was shown to be highly
predictive of mortality, from as early as 3 months. These results suggest that daily FVC recording might
have value as an efficacy end-point, where its use could shorten the duration of early-phase clinical trials.
In the clinical arena, trends detected by daily FVC monitoring might also alert the patient and physician
earlier to disease progression or the onset of an acute exacerbation episode.
Grouped analyses of patients with FVC ⩾50% predicted in the ASCEND and INPULSIS trials showed the
utility of FVC as a marker of IPF progression and its sensitivity to treatment-associated change [19, 31].
However, many patients presenting to clinical practice with FVC <50% predicted and/or significantly
reduced DLCO consequent upon severe fibrotic disease, coexisting chronic obstructive pulmonary disease
or pulmonary hypertension are excluded from trials. Trial findings may not entirely apply to most patients
in the real world because their disease severity falls within a much broader range of physiological
impairment than in trial settings. What has been directly relevant to clinical practice is the demonstration
in INPULSIS-ON, the open-label extension of the INPULSIS trials of nintedanib in IPF, that FVC decline
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is comparable over a 48-week period of treatment between individuals whose FVC lay on either side of the
50% predicted mark [32].
The STEP-IPF study of sildenafil in advanced IPF enrolled patients with DLCO of <35% of predicted [33].
The mortality rate of 13% at 28 weeks in this cohort of subjects with severe disease contrasts with the
2-year 13.7% fatality rate revealed by the pooled analysis of the placebo arms of the INSPIRE and
CAPACITY trials that included patients with “mild-to-moderate” IPF [34]. These results demonstrate the
correlation between risk of death and IPF disease severity. In reality, however, it is precisely because recent
trials have been beset by a low mortality rate that they have had to rely on pooled data analyses to
highlight the potential effect of antifibrotic therapy in modulating the risk of disease-related death.
Similarly, pooled and meta-analyses of clinical trials of pirfenidone have shown that the relative risk of
death in IPF is reduced over 120 weeks of treatment [35]. It seems that continued treatment with
pirfenidone in those whose disease has progressed, defined as ⩾10% absolute decline in FVC during the
first 6 months of treatment, can still be beneficial as reflected in a lower risk of subsequent FVC decline or
death [36].
Post hoc subgroup analyses of both pirfenidone and nintedanib trials have shown that patients with
so-called “preserved lung volume” (FVC >90% predicted in the nintedanib subgroup and FVC ⩾80% in
the pirfenidone subgroup) have a rate of FVC decline comparable to those with moderate or severe disease
and that they also benefit from antifibrotic therapy to the same extent as patients with more contracted
lung volume [37, 38]. Hence, once a confident diagnosis of IPF has been made, it could be reasonably
questioned if the precise categorisation of disease into very mild, mild or moderate groups is necessary for
eligibility for antifibrotic therapy. Crucially, these observations highlight the importance of securing a
timely diagnosis of IPF, but this process suffers from the absence of clinical tools to distinguish early IPF
from insignificant interstitial lung abnormalities that are increasingly encountered in chronic smokers.
Such changes, whether or not representing smoking-related ILD, often remain subclinical and, for the
most part, do not progress over time [39, 40].
Severe IPF appears to be also associated with a higher risk of acute exacerbations [31]. It is thus possible to
postulate that by slowing the rate of progression, quantified as a delay in the loss of FVC, antifibrotic
strategies might delay the time to exacerbation. It may now be difficult or impossible to study this premise,
as it would be unethical to withhold antifibrotic treatment to patients with a certain severity of IPF while
prospectively monitoring them for the development of acutely deteriorating disease.
Data regarding change in percentage-predicted DLCO as a marker for predicting survival in IPF are
inconclusive. A retrospective analysis of treatment with interferon-γ1b failed to identify a threshold of
DLCO change that predicted mortality, although an earlier study showed that trends in DLCO levels might
provide important information for determining mortality [41, 42]. It has latterly been proposed that
baseline DLCO outperforms baseline FVC as a prognostic factor in IPF [25]. An analysis of a UK
prospective IPF cohort has similarly suggested that DLCO is better than FVC as a predictor of mortality,
especially in patients with specific risk factors that portend a worse prognosis, such as concomitant
emphysema and pulmonary hypertension [43]. In a study of patients with IIP, both baseline and 6-month
decline in KCO (diffusing capacity adjusted for functioning alveolar volume) were associated with increased
early and overall mortality [44]. These results suggest that FVC may not be the sole or even the best
predictor of fibrotic disease progression or mortality in real-world clinical cohorts when serial
physiological changes are assessed.
Spirometric parameters have certain limitations when used longitudinally. It is difficult to ascertain
whether longitudinal change is due to test variability or reflects a true change in lung function [45]. FVC
can be poorly sensitive to change and marginal changes of 5–10% are difficult to interpret in an individual
[46]. Measurements of DLCO and KCO are less widely available and more difficult to perform in
individuals with severe disease. They are also subject to greater intra-individual and inter-laboratory
variability than FVC and are sensitively affected by comorbid conditions such as emphysema or
pulmonary hypertension.
Functional markers of disease severity in IPF
Baseline and change at 6 months of the 6-min walk distance (6MWD) have been reported as independent
predictors of mortality in IPF [47]. The MCID for 6MWD has been estimated to be between 21.7 m and
37 m in a cohort of patients with IPF allocated to the placebo arms of the CAPACITY trials [48]. This, as
well as findings from an earlier interferon γ-1b trial, confirm the utility and validity of the 6MWD as a
measure of disease status and end-point for IPF clinical trials [49]. Desaturation on 6MWT has also been
associated with mortality in IPF, but measurement of oxygen desaturation is hampered by poor
reproducibility [50, 51]. Interestingly, abnormal heart rate recovery after 6MWT or the difference between
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the heart rate at the end and at 1 min after completion of the test has shown to be an independent
predictor of mortality and pulmonary hypertension in patients with IPF [52, 53].
In conclusion, although it is increasingly accepted that a number of factors such as interval change in
FVC, dyspnoea and 6MWD can individually or collectively correlate with a particular severity of IPF, this
does not equate to being reliable predictors of longitudinal disease progression. Indeed, when incorporated
within clinical prediction models, they perform better at predicting binary outcomes like respiratory
hospitalisation and death than intrinsic disease progression [54]. This highlights the need for the
development and validation of tools that have the potential to predict disease behaviour and risk of
progression which would be useful in clinical decision-making and designing future clinical trials.
Radiological markers of disease severity
Semi-quantitative computed tomography
The most pertinent computed tomography (CT) patterns of fibrotic ILD are reticulation, traction
bronchiectasis, honeycombing and ground-glass opacification, which have specific and broadly agreed
definitions [55].
Visual assessment of disease extent can be reported with poorly defined terms like mild, moderate or
severe, or can be reported as an estimate of the percentage of the lung affected to the nearest 5%, 10% or
25%. This mental mapping of the disease extent may be easier to do on a single CT section than from a
three-dimensional display of the lung [46]. To address this issue, a hybrid method of dividing the lung
into three or five sections based on the corresponding mediastinal structures has been widely used [9, 56, 57].
Several studies have investigated the relationship between extent of fibrosis on CT and outcomes at a single
point in time. Baseline patterns, in particular honeycombing, the hallmark of UIP/IPF, have also been
widely investigated as a marker of outcome (with some disparity in study results) [58–63]. LYNCH et al.
[58], using non-volumetric CT, found that the overall extent of fibrosis, defined as the extent of
reticulation and honeycombing on CT, was an independent predictor of mortality in IPF. Similarly, studies
by SHIN et al. [64] and EDEY et al. [61] found that the overall extent of fibrosis indicated a poor prognosis
in populations that contained not only patients with IPF but other fibrotic IIPs. The results from these
studies indicate that increasing disease extent on CT is undeniably related to adverse prognosis in IPF.
However, clinically useful staging systems based on imaging (such as those used in the setting of cancer
staging) traditionally require absolute cut-offs that demarcate different prognostic groups. In this regard,
there is a paucity of research in IPF. In one study by ROMEI et al. [65] it was shown that baseline
honeycombing >25%, fibrosis score >30% and traction bronchiectasis in all four lobes were indicators of
poor outcome.
The relationship between CT patterns, and not just disease extent, has also been studied in IPF. In a study
of 98 patients with histologically confirmed diagnosis of IPF, SUMIKAWA et al. [66] categorised patients into
three groups: 1) definite UIP; 2) consistent with UIP; and 3) suggestive of an alternative diagnosis. No
significant difference in prognosis between the different groups was found, but prognosis was influenced
by traction bronchiectasis and overall fibrosis scores. More recently, there are data suggesting that many
cases with a possible UIP pattern (i.e. no honeycombing on baseline high-resolution CT (HRCT)) follow a
comparable trajectory to those with a definite UIP pattern (i.e. honeycombing on baseline HRCT). A post
hoc subgroup analysis from the INPULSIS trials suggested that patients with a diagnosis of IPF based on
possible UIP pattern on HRCT showed similar rate of decline in FVC as patients with definite UIP pattern
based on the presence of honeycombing on HRCT or histological diagnosis of UIP [63].
There are fewer studies looking at serial CT to monitor disease progression in IPF using a visual
assessment of disease extent. LEE et al. [67] studied 154 patients who had fibrotic IIP with little
honeycombing (defined as <5%). The authors found that an increase in honeycombing and reticulation on
serial CT was associated with poorer outcomes. However, on multivariate analysis, the extent of fibrosis on
the baseline scan remained the only predictor of mortality. By contrast, in another study, YAMAUCHI and
colleagues [62] demonstrated that the development of honeycombing on HRCT during follow-up in 30
patients with classical or possible IPF did not affect prognosis. HWANG et al. [68] also looked at the
prognostic value of CT at baseline and on sequential evaluation in a heterogeneous group of fibrosing IIPs.
The investigators found both the extent of honeycombing at baseline and its progression on serial imaging
to be independent determinants of mortality. A study by ODA et al. [69] was particularly notable as it
studied patients over a comparatively shorter time frame. The authors found that increasing visual fibrosis
score on a 6-month follow-up CT was a significant predictor of poorer outcomes, even in a subgroup of
patients with no decline in FVC. The results from these studies illustrate the lack of clear consensus about
both the utility of subjectively comparing fibrosis extent on serial CT, as well as its significance. In part,
this may reflect the difficulties in visually comparing overall fibrosis extent over the entirety of a thoracic
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CT. Nevertheless, there are also instances where disease progression on CT is unequivocal, which may
confirm suspicions of clinical deterioration.
Quantitative computed tomography
Quantitative CT is a relatively new and promising domain in the evaluation of disease extent in ILD.
Methods vary from simple histogram analysis to more complex forms of textural based analysis and
machine learning. In the former, histogram-based measurements such as mean lung attenuation and
amount of skewness and kurtosis from CT images have been found to correlate with physiological
measures of disease severity [46, 70–72].
Automated textural analysis typically requires, as an initial step, trained observers labelling regions of
interest in the lung according to a specific pattern (e.g. normal, honeycombing, etc.). Textural
characteristics of these regions are then extracted. A machine-learning algorithm is then used to develop a
predictive model for specific CT patterns [46]. MALDONADO et al. [73] used a novel computer-aided system
called CALIPER to quantify fibrosis in IPF based on unique HRCT texture patterns for ground-glass
opacification, honeycombing and reticulation. The authors evaluated changes in those HRCT-derived
patterns between two time points (3–15 months apart) and showed that changes in reticulation and total
fibrosis were predictive of survival. Recently, JACOB et al. [74] compared quantitatively assessed disease
extent on HRCT with visual scores in IPF. When the two techniques were validated against lung function
test parameters, CALIPER was superior to the traditional visual scores. The investigators also found that a
novel parameter called pulmonary vessel volume (PVV) had stronger correlations with lung function tests,
indicating that it may have potential in assessing disease severity in IPF. The same group demonstrated
that CALIPER-derived honeycombing and PVV were more accurate than traditional fibrosis scores in
predicting mortality, independent of physiological indices [75]. While quantitative disease assessment in
lung fibrosis has been around for some years, its application in monitoring disease in therapeutic trials has
recently gained interest. One notable recent study in this field by SALISBURY et al. [76] involved textural
analysis of a cohort of IPF patients enrolled in a clinical therapeutic trial using a novel adaptive multiple
features method (AMFM) at two time points. The investigators observed that AMFM-measured fibrosis
was independently related to the risk of disease progression as judged by a number of clinical and
physiological measures, including the composite gender–age–physiology (GAP) score (a score accounting
concurrently for patient age, gender, FVC and DLCO, where a higher score is associated with increased risk
of mortality) and smoking history. These studies suggest that quantitative lung fibrosis assessment has the
potential to emerge as a powerful biomarker of IPF severity and disease progression, but future work is
required to validate its role.
Strengths and limitations of CT in staging of IPF
There are several potential advantages to using CT for staging patients in IPF. The acquisition of images is
fast and routinely available, allowing adequate assessment of stable as well as very ill patients. Coexisting
conditions and complications such as emphysema, pulmonary hypertension and acute exacerbations can
be effectively and simultaneously assessed on CT. Moreover, CT findings correlate accurately with
functional impairment [9]. One of the main limitations with CT is the lack of standardised acquisition
protocols. For example, non-contiguous CT is still routinely performed at some centres, and many of the
studies that report on the role of CT in prognostication in IPF used interspaced CT. Because volumetric
CT captures images of the entire thorax, it is assumed that it can produce more accurate information
about disease extent, in particular with respect to serial change. However, the extent to which this is the
case is not truly known. The state of lung inflation at the time of image acquisition also impacts lung
density, so standardised breathing instructions at the time of image acquisition are essential for congruous
results. Variation in lung density is at its lowest at full inspiration, when consistent results are thus more
likely to be achievable [46].
The interobserver agreement for CT patterns, and in particular honeycombing, remains suboptimal due to
concomitant conditions such as emphysema or traction bronchiectasis that mimic honeycombing [7, 67,
77]. WATADANI et al. [77] used a five-point scale to assess agreement for honeycombing on CT amongst 43
observers in 80 patients with IPF. In almost a third of the cases, there was disagreement on the
identification of honeycombing due to the conditions resembling honeycombing on CT. Interobserver
variation in assessing progression of disease on CT has been less widely studied.
Visual scoring of the disease extent on CT can be time-consuming, and its applicability in clinical practice
is limited. There is no standardised method of visual scoring, and its value in serial assessment is not fully
validated [46]. Furthermore, most data are derived from retrospective studies with varying follow-up
intervals between serial CT scans. Additionally, retrospective studies that include clinically indicated CT
scans may be biased towards including patients with disease deterioration. However, retrospective studies
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using real-world clinical data have the advantage of incorporating patients with varying extents of disease
severity.
Quantitative CT has the potential to diminish but not entirely eliminate interobserver disagreement,
considering that the software remains dependent on training by expert radiologists, who are subject to
interobserver variability. In addition, to date, it has primarily focused on evaluating the extent of
parenchymal abnormalities as a surrogate for fibrosis severity, with less emphasis on other variables such
as lung volumes [73, 74] or the degree of traction bronchiectasis. The issue of CT protocol standardisation
is nevertheless equally important, if not more so, for automated evaluation. Furthermore, issues such as
cost, reproducibility and validity need to be addressed before such computer-aided systems can routinely
be used in clinical practice or clinical trials.
Positron emission tomography CT
There is limited evidence that 18F-FDG positron emission tomography (PET) can be used in the
assessment of IPF or other forms of IIPs [78–82]. GROVES et al. [79] investigated the relationship between
mean maximal standard uptake value (SUVmax) values and lung function parameters (FVC and DLCO) in
a cohort of 36 patients with diffuse lung disease (18 with IPF). They found moderate correlations between
pulmonary 18F-FDG uptake and lung function parameters. The investigators also found that glucose
metabolism was higher in areas with reticulation/honeycombing than in regions with ground-glass
opacification (SUVmax=3.0+/−1.0 and 2.1+/−0.4 respectively, p=0.007). In a study of 50 patients with
various IIPs comprising IPF, nonspecific interstitial pneumonia (NSIP) and organising pneumonia, UMEDA
and colleagues [81] investigated the value of dual-point 18F-FDG PET CT (performed 1 h and 3 h post
18F-FDG injection) in the diagnosis and prognostication of IPF. The authors used SUV values at the two
points (early SUV at 1 h and delayed SUV at 3 h) to calculate the retention index of SUV (RI-SUV) and
then compared the results with serial lung function tests performed at 3 and 12 month intervals from the
PET CT. They found that an early SUV cut-off value of ⩾1.5 had a high sensitivity and specificity (90.9
and 94.3, respectively) in distinguishing between organising pneumonia and IPF/NSIP. The RI-SUV was
significantly higher in patients with IPF or NSIP that had a decline in lung function after 1 year follow-up.
The same investigators also reported that positive RI-SUV (⩾0%) predicted a decline in lung function and
mortality [82]. In this cohort, patients with positive RI-SUV tended to have more fibroblastic foci, and the
authors concluded that RI-SUV may be associated with the degree of fibroblast activity in patients with IPF.
Magnetic resonance imagining
There are a handful of studies investigating various magnetic resonance imaging (MRI) sequences such as
spin echo, inversion recovery or dynamic post-contrast T1-weighted multishot turbo field-echo sequences
in IPF [83–86]. The principle for the majority of these studies is based on the assumption that, in contrast
to normal lung tissue, fibrotic lung tissue demonstrates significant contrast enhancement on late-enhanced
MRI sequences, which is a well-established fact in the assessment of myocardial fibrosis on cardiac MRI.
In a pilot study of 10 patients with IPF and 10 healthy controls, MIRSADRAEE and colleagues studied T1
mapping at 3T MRI [87]. In this study, a modified look-locker inversion recovery (MOLLI) sequence was
used during a 15–20 s breathhold on a single pre-selected slice based on HRCT findings. MOLLI
sequences were acquired prior and at 15, 25, 30 and 35 min post gadolinium administration. The authors
found that the fibrotic lung had the highest pre-contrast T1 and at 10 min post gadolinium administration,
the control lung had a significantly shorter T1 compared to both fibrotic and morphologically normal
lung in IPF. At 20 min, T1 for fibrotic lung continued to decrease, but T1 for morphologically normal
lung in IPF did not significantly change after 10 min. This demonstrates that fibrotic lung shows delayed
enhancement compared with morphologically normal lung. T1 mapping at 3T MRI in IPF can potentially
differentiate between normal lung and fibrotic tissue and may be valuable in detecting early fibrosis and
assessing disease activity if validated in larger cohorts.
Nevertheless, the use of MRI in IPF remains limited. This is because of a number of limiting factors
associated with MRI in the lungs. The thick slices routinely used in MRI diminish the precise anatomical
evaluation of interstitial changes. Furthermore, issues such as low proton density, fast signal decay due to
artefacts/air tissue interfaces and prolonged acquisition times in patients with severe dyspnoea can reduce
image quality and result in reduced diagnostic accuracy [84]. The majority of studies investigating the role
of MRI in IPF are limited by small-sized cohorts and lack of validation. The other important issue is that
the possible impact of various patterns (definite UIP, possible UIP and inconsistent with UIP) on MRI
signal characteristics has not been investigated previously.
Composite measures of disease severity
Clinical prediction models in IPF may be enhanced by the use of composite indices to increase the
accuracy and sensitivity of severity stratification and prognostication [18]. The ideal non-invasive
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composite measure should incorporate different disease domains that have individually been shown to be
reproducible, discriminant and sensitive to change over time. Several multidimensional risk prediction
models integrating various clinical, physiological and radiological variables have been validated in IPF [7–
9, 88–90] (table 1). These composite staging systems have been demonstrated to be better at predicting
baseline and longitudinal mortality risk than their individual components. For example, the composite
physiologic index (CPI) (table 1) has been shown to correlate better with disease extent on HRCT than
individual functional variables, and allows correction of the confounding effects of emphysema on lung
function parameters [9]. Another system called the GAP staging system, which incorporates gender, age,
FVC and DLCO, has been shown to be predictive of death or lung transplantation but not of the future rate
of decline in pulmonary function [91]. This model performs equally well when substituting DLCO for
visually assessed CT fibrosis extent (CT-GAP score) [8].
TABLE 1 Comparison of mortality risk scoring systems in idiopathic pulmonary fibrosis
Variables Predictive value Advantages Disadvantages
Composite
physiologic
index (CPI) [9]
DLCO % pred
FVC % pred
FEV1 % pred
Correlation with
morphologic extent:
CPI=91.0
−(0.65×DLCO)
−(0.53×FVC)+(0.34
FEV1)
More accurate
predictor of
mortality than
individual
functional variables
Correction for confounding effects
of emphysema
Retrospective data;
measurement variability in DLCO;
not yet been replicated
Du Bois et al.
model [7]
Age (0–8 pts)
24-week history of
respiratory
hospitalisation
(0 or 14 pts)
FVC % pred (0–18 pts)
24-week change in FVC
(0–21 pts)
1-year mortality risk
Examples total score:
• 0–4 pts: <2%
• 22–29 pts: 10–
20%
• 38–40 pts: 40–
50%
• >50 pts: >80%
Easily and reliably evaluable;
longitudinal variables
Assessed in cohorts with only mild
to moderate physiological
impairment at baseline and with
exclusion of severe emphysema
Gender–age–
physiology
(GAP) model
[82]
Gender (0–1 pts)
Age (0–2 pts)
FVC % pred (0–2 pts)
DLCO % pred (0–3 pts)
Cumulative mortality
at 1, 2, 3 years
Examples 1-year
mortality risk:
Stage I (0–3 pts): 6%
Stage II (4–5 pts):
16%
Stage III (6–8 pts):
39%
Externally validated
GAP calculator as add-on tool
for more precise estimation of
risk
Retrospective data;
possible referral bias
(academic centres);
tends to overestimate risk
Longitudinal GAP
model [83]
Gender (0–1 pts)
Age (0–4 pts)
FVC % pred (0–15 pts)
24-week relative
change in FVC (0–12
pts)
DLCO % pred (0–23 pts)
Respiratory
hospitalisation
(last 24 weeks)
(0 or 14 pts)
1 and 2-year mortality
risk
Examples 1-year
mortality risk:
• 0–10 pts: <2%
• 27–34 pts: 10–20%
• 43–45 pts: 40–50%
• 55–60 pts: ⩾80%
Longitudinal risk assessment;
prospective data
No external validation
CT-GAP model
[8]
Gender
Age
FVC % pred
Semi-quantitative CT
fibrosis score
Cumulative mortality
at 1, 2, 3 years
Examples 1-year
mortality risk:
Stage I (0–3 pts): 5%
Stage II (4–5 pts):
19%
Stage III (6–8 pts):
43%
Accuracy comparable to that of the
original GAP model; alternative
model when DLCO unmeasurable
or not available; externally
validated
Retrospective data;
requires expertise in
quantification of CT disease
extent
DLCO: diffusing capacity of carbon monoxide; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; CT: computed tomography; %
pred: % predicted; pts: points. Reproduced and modified from [89] with permission from the publisher.
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A strategy to improve the sensitivity of future composite measures would be to integrate independent
predictors of disease progression, such as serial change in FVC, with decline in 6MWD and/or serial
change in HRCT fibrosis score [18, 92]. Recent advances in our understanding of the complex
pathogenesis of IPF have increased endeavours aimed at identifying and validating specific biological
determinants that hold greater promise for diagnostic and prognostic applicability. Intuitively, the next
step in the development of composite measures that can more accurately assess IPF severity and
progression would probably include combinations of biomarkers.
Histopathological staging in IPF
A histologic pattern of UIP is associated with worse prognosis [93] and is characterised by the presence of
fibroblastic foci in the interface between the fibrotic and the relatively spared regions of the pulmonary
lobule [94]. Nevertheless, survival does not differ in patients with concordant UIP (UIP in all lobes) versus
discordant UIP (UIP in at least one lobe) [93]. Although this indicates that the mere presence of UIP on
pathology is significantly prognostic, there is also evidence that the number of fibroblastic foci on lung
biopsy is related to outcomes [4, 95]. Recently, WALSH and colleagues [96] investigated the relationship
between fibroblastic foci and individual CT patterns of fibrosis. They found that severity of traction
bronchiectasis correlated most strongly with fibroblastic foci profusion on histopathological analysis,
providing an insight into the pathological processes behind traction bronchiectasis.
Pathological staging does have limitations. Surgical biopsy is required for histopathological diagnosis, but
this only applies to perhaps 15% of IPF cases because of the severity of the disease at the time of diagnosis
and the risks of biopsy [97]. Moreover, there can be suboptimal agreement among pathologists regarding
the type of IIP. NICHOLSON et al. [98] showed that a 100% confidence level for a single pathologically made
diagnosis was only reached in 39% of cases. The agreement amongst pathologists was poor for NSIP
(κ=0.32) and fair for UIP (κ=0.49).
Summary
In conclusion, the accurate evaluation of disease severity in IPF and predicting disease progression is
challenging and somewhat limited by a lack of standardised and validated measures. Pulmonary function
parameters at a single time point do not reliably predict disease behaviour and, despite multiple attempts
in the last 20 years or so, HRCT-quantified disease extent on sequential imaging has not been established
as a reliable marker of disease progression. With advances in our understanding of disease behaviour in
IPF, there are novel tools such as biological mediators or quantitative CT-derived lung fibrosis measures
that can lead to the development of more robust staging systems, either in isolation or in combination.
Future studies focusing on this area of research are certainly required to establish such systems.
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